Fisher & Paykel HealthcareFSPKF +9.59%90 3-Year ROIIC % is 74.72 as of Mar. 2026, which is 191% above its 10-year median of 25.66. GuruFocus rates FSPKF with a GF Score™ of 90/100 and a GF Value™ of $25.21 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 86.23% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Fisher & Paykel Healthcare's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 74.72%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Fisher & Paykel Healthcare's 3-Year ROIIC % or its related term are showing as below:
FSPKF's 3-Year ROIIC % is ranked better than 86.23% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 1.67
vs FSPKF: 74.72
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Fisher & Paykel Healthcare 3-Year ROIIC % Related Terms
Fisher & Paykel Healthcare 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FSPKF vs ISRG, BDX, MDLN: 3-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Fisher & Paykel Healthcare (FSPKF) has a 3-Year ROIIC % of 74.72 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Fisher & Paykel Healthcare and its competitors. This is 191% above median its historical median of 25.66. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #110 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 13.8%.
Is Fisher & Paykel Healthcare's 3-Year ROIIC % too high?
Fisher & Paykel Healthcare's current 3-Year ROIIC % of 74.72 is 191% above median its 10-year median of 25.66. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.67. Fisher & Paykel Healthcare's value of 74.72 is 4374.3% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #110 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's 3-Year ROIIC % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #110 out of 799 companies for 3-Year ROIIC %. This places Fisher & Paykel Healthcare in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.67. Fisher & Paykel Healthcare's value of 74.72 is 4374.3% above this benchmark. While the company's 10-year median is 25.66 vs. the industry median of 1.67, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.67, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current 3-Year ROIIC % of 74.72 is 4374.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current 3-Year ROIIC % is 74.72, which is 191% above median its own 10-year median of 25.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (FSPKF) is currently considered Modestly Undervalued. The stock's GF Value™ is $25.21, compared to a current price of $22.52 — trading 10.7% below its estimated fair value. The current 3-Year ROIIC % is 74.72, which is 191% above median its 10-year median of 25.66 and 4374.3% above the Medical Devices & Instruments industry median of 1.67. Fisher & Paykel Healthcare's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Fisher & Paykel Healthcare (FSPKF), the current 3-Year ROIIC % is 74.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (FSPKF) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of $22.52 is trading 10.7% below its estimated GF Value™ of $25.21.
GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.
Key valuation signals for FSPKF:
3-Year ROIIC %: 74.72 (191% above median its 10-year median of 25.66)
GF Value™: $25.21 vs. price of $22.52 (10.7% below fair value)
Industry Position: 4374.3% above the Medical Devices & Instruments median (#110 of 799)
No single metric tells the full story. See the FSPKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
90GF Score
Get the complete analysis for FSPKF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSPKF has been successfully added to your 
